smage col646\$

torney's Docket No. PP17201.003 (035784/240412)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Yre: Shirley et al. - Confirmation No.: 3374 Appl. No.: 10/035,397 Group Art Unit: 1646

Filed: October 25, 2001 Examiner: Janet L. Andres

For: HSA-FORMULATIONS OF INTERFERON-BETA

January 23, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Sir:

Attached is a list of documents on form PTO-1449 together with copies of each identified document. Also enclosed is a translation or a concise explanation of each non-English language document.

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Applicants note that WO 89/05158 listed as Cite No. 33 is related to U.S. Patent No. 5,004,605 (Cite No. 8 on the PTO Form 1449 of the Information Disclosure Statement filed May 17, 2002); and CA 2,304,808 listed as Cite No. 37 is an English equivalent of WO 99/15193 (Cite No. 29 on the PTO Form 1449 of the Information Disclosure Statement filed December 13, 2002).

Applicants wish to bring to the Examiner's attention WO 99/51272 listed as Cite No. 35. This published PCT International Application corresponds to copending U.S. Patent Application No. 09/285,429, filed April 2, 1999.

01/28/2004 HGUTEMA1 00000103 10035397

01 FC:1806

180.00 DP

In re: Shirley *et al.*Appl. No.: 10/035,397
Filed: October 25, 2001

Page 2

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(c), before final Office Action or Allowance, whichever is earlier. A check for the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. The Commissioner is authorized to charge any additional fee, or credit any refund, to our Deposit Account No. 16-0605.

Respectfully submitted,

Leslie T. Henry

Registration No. 45,714

CUSTOMER NO. 00826 ALSTON & BIRD LLP

Bank of America Plaza 101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200 Fax Raleigh Office (919) 862-2260 CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,

on January 23, 2004

I vnda-Id/Pixley

•		OIPE								
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				Complete if Known						
Substitute for form 1449A/PTO JAN 2 6 2004				Application Number			10/035,397			
Substitute for form 1449A/PTO (Revised 10/2001)			Fi	Filing Date			October 25, 2001			
(Q ₁ ,,,,,,,, .				First Named Inventor			Shirley			
INFORMATION DISCLASURE STATEMENT BY APPLICANT			Gı	Group Art Unit			1646			
(Use as many sheets as necessary)			Examiner Name			Janet L. Andres				
Sheet	1 1	of 1	<u> A</u>	Attorney Docket Number			PP17201.003 (035784/240412)			
		TT	c p	ATENT DO	CIN	#FNITC				
	Τ	Document Number	5. PA	ALENI DO	CUN	ILNIS				
Examiner	Cite					Name	of Patentee or	1	Pages, Columns, Lines, Where	
Initials*	No.					Applicant of Cited Document		Relevant Passages of Relevant Figures Appear		
p 	Ì					-t	-			
			 					-		
	<u> </u>									
	Т		EIGN	PATENT I	<u> </u>	UMEN	TS	D		
Examiner	Cite	Foreign Patent Document		Publication Date N		Name of	Patentee or	Pages, Columns, Lines, Where Relevant	T	
Initials	No.	Country Code - Number Kind Code (if known)		MM-DD-YYYY A			nt of Cited	Passages or Relevant	-	
						Docume	nt	Figures Appear	ļ	
	32	WO 89/02750		04-06-1989	1	Cetus (Corporation			
	33	WO 89/05158		07-02-1998 Bioger		Cetus (Corporation			
	34	WO 98/28007				Inc.				
	35	WO 99/51272				Chiron	Corporation			
	36	36 EP 0 284 249		09-28-1988 Inte		Interfe	feron Sciences,			
						Inc.				
	37	37 CA 2,304,808				Dr. Re	ntschler			
						Biotechnologie				
	<u></u>					GMBE	[& Co. KG, DE			
	·		OTH	IER DOCU	MEN	NTS				
		Include name of the author (in CAP	ITAL	LETTERS), title	e of th	ie article (when appropriate), t	itle of the item		
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s								•		
Examiner Initials	Che No.	city and/or country where published	i.					1		
		**************************************					***************************************			
		A STATE OF THE STA		***************************************	***************************************					
······································				······································	***************************************					
		I								
Examiner	1					Dat	۹ ا			

		
Examiner	Date	
Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.